A NOVEL REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR SIMULTANEOUS ESTIMATION OF DROTAVERINE HYDROCHLORIDE, ETHAMSYLATE, AND TRANEXAMIC ACID IN TABLET DOSAGE FORM
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i6.24777Keywords:
Drotaverine hydrochloride, Ethamsylate, Tranexamic acid, Reversed-phase high-performance liquid chromatography, International conference on harmonization, ValidationAbstract
Objective: The objective of this study was to develop and validate a simple, rapid, accurate, and precise reversed-phase high-performance liquid chromatographic method (RP-HPLC) for simultaneous estimation of drotaverine hydrochloride, ethamsylate, and tranexamic acid in tablet dosage form.
Methods: The chromatographic separation was achieved using stationary phase C18 shim-pack GIST (150 mm ×4.6 mm, 5 μ) column and mobile phase consists of methanol:potassium dihydrogen phosphate buffer (pH 3.0 adjusted using orthophosphoric acid) in a ratio of 30:70 v/v, with a flow rate of 1 ml/min and ultraviolet detection at 220 nm.
Results: The retention time of tranexamic acid, ethamsylate, and drotaverine hydrochloride was found to be 3.6, 4.0, and 5.0 min, respectively. The developed method was validated for linearity, accuracy, precision, and robustness according to the international conference on harmonization guidelines. The method was found to be linear over the tested concentration range of 48–112 μg/ml for drotaverine hydrochloride, 150–350 μg/ml for ethamsylate, and 150–350 μg/ml for tranexamic acid. Mean percentage recoveries were found to be 99.59 for drotaverine hydrochloride, 99.27 for ethamsylate, and 99.71 for tranexamic acid. The correlation coefficient for all components was found to be more than 0.999.
Conclusion: A novel RP-HPLC method was developed and validated for simultaneous for the estimation of drotaverine hydrochloride, ethamsylate, and tranexamic acid to their commercially available tablet dosage form.
Downloads
References
Budawari S. The Merck Index. 13th ed. Whitehouse Station, N.J: Merck and Co Inc.; 2003. p. 609, 9640.
Elks J, Ganellin CR. The Dictionary of Drugs: Chemical Data, Structures and Bibliographies. 1st ed. London; Royal; 1990. p. 472.
Merck and Company. The Merck Index-An Encyclopaedia of Chemicals, Drugs and Biologicals. 13th ed. USA: Merck and Company; 1989. p. 3757, 9648.
Martindale, The extra pharmacopoeia, The complete drug reference. 34th edn. Pharmaceutical press, London; Royal; 2005. p. 749, 760.
Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F, et al. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology 2005;102:727-32.
Her Majesty’s Stationary Office. British Pharmacopeia. Vol. I, II. London: Her Majesty’s Stationary Office; 2004. p.758, 1960.
Jameelunnisa B, Abdul R. Spectrophotometric determination of drotaverine in tablets. Asian J Chem 2008;20:4173-84.
Jyotesh J, Riddhish P, Divyesh V, Renu C, Shailesh S. Dual wavelength spectrophotometric method for simultaneous estimation of drotaverine hydrochlorideand aceclofenac in their combined tablet dosage form. Int J Pharm Pharm Sci 2010;4:76-9.
Roshan I, Kaushik KV, Diptish KN. Spectrophotometric methods for simultaneous estimation of ethamsylate and tranexamic acid from combined tablet dosage form. Int J Chemtech Res 2010;2:74-8.
Reddy NK, Potawale SE, Gabhe SY, Mahadik KR. HPTLC double development and validation of mefenamic acid and tranexamic acid in combined tablet dosage form. Pharm Sinica 2013;4:16-21.
Suganthi A, Thengungal KR. Stability indicating hplc method for simultaneous determination of drotaverine and aceclofenac. Int J Pharm Pharm Sci 2011;3:245-50.
Srinivasa RA, Pavankumar KL, Satyanarayana P, Subrahmanya S. Simultaneous estimation of mefenamic acid, ethamsylate and tranexamic acid in bulk and pharmaceutical formulations by RP-HPLC method. Am J Pharm Tech Res 2015;5:402-14.
ICH. Stability Testing of New Drug Substances and Products (Q1AR2). Geneva: International Conference on Harmonization, IFPMA; 2003.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
